Dr. Martens (LON:DOCS) Trading Down 11.6% – Here’s Why

Shares of Dr. Martens plc (LON:DOCS) were down 11.6% on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.90. Approximately 9,032,986 shares were traded during mid-day trading, an increase of 342% from the average daily volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DOCS shares. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research note on Tuesday. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Price Performance

The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The firm has a market cap of £657.97 million, a P/E ratio of 40.04, a PEG ratio of 6.40 and a beta of 0.11. The stock’s 50-day simple moving average is GBX 75.76 and its two-hundred day simple moving average is GBX 83.16.

Dr. Martens (LON:DOCS) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities research analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Insider Activity

In other Dr. Martens news, insider Robert Hanson bought 96,000 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, with a total value of £75,840. Insiders purchased a total of 97,130 shares of company stock worth $7,673,816 in the last ninety days. 2.79% of the stock is owned by insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.